Fig.1From: Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in ChinaCost-effectiveness analysis PartSA partitioned survival analysis, QALY quality adjusted life year, WTP willingness-to-payBack to article page